Therapy Areas: Infectious Diseases
ABL Texcell Diagnostics acquires IntegraGen assets to expand into precision oncology
12 October 2026 - ABL Texcell Diagnostics (Euronext Paris:ABLD), a provider of molecular biology tests, said on Monday that it has acquired IntegraGen's assets and business operations following a...
Roche Diagnostics supplies molecular testing instruments to support Ebola response in the DRC
7 October 2026 - Swiss healthcare company Roche (SIX: RO, ROP; OTCQX: RHHBY) announced on Wednesday that it has supplied two molecular testing instruments to the Institut National de Santé Publ...
Lakewood-Amedex Biotherapeutics reports positive data for clinical candidate Nu-3 in diabetic foot ulcers
29 September 2026 - Lakewood-Amedex Biotherapeutics Inc (NASDAQ:LABT), a clinical-stage biotechnology company focused on advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials f...
QIAGEN completes US QIAstat-Dx bloodstream infection portfolio with FDA clearance
28 September 2026 - Netherlands-based holding company QIAGEN N.V. (NYSE:QGEN) (Frankfurt Prime Standard:QIA) announced on Monday that it has received US Food and Drug Administration (FDA) clearance fo...
Armata Pharmaceuticals announces receipt of FDA Breakthrough Therapy Designation for AP-SA02
14 September 2026 - Biotechnology company Armata Pharmaceuticals Inc (NYSE American: ARMP) reported on Monday that it has received U.S. Food and Drug Administration Breakthrough Therapy designation fo...
Lakewood-Amedex Biotherapeutics to present at H.C. Wainwright 28th Annual Global Investment Conference
9 September 2026 - Clinical-stage biotechnology company Lakewood-Amedex Biotherapeutics Inc (NASDAQ:LABT) announced on Tuesday that its CEO, Kelvin Cooper, Ph.D., will deliver a virtual presentation a...